NCT06358053View on ClinicalTrials.gov

CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2028

Conditions
Cervical CancerAnal CancerHead and Neck CancersOther Solid Tumors
Interventions
DRUG

CRTE7A2-01 TCR-T cell therapy

Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell

Sponsors
All Listed Sponsors
lead

Corregene Biotechnology Co., Ltd

INDUSTRY